Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

PURPOSE: Despite impressive response rates following adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, improvement is needed to increase the efficacy and broaden the applicability of this treatment. We evaluated the use of vemurafenib, a smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Borch, Troels Holz, Harbst, Katja, Rana, Aynal Haque, Andersen, Rikke, Martinenaite, Evelina, Kongsted, Per, Pedersen, Magnus, Nielsen, Morten, Kjeldsen, Julie Westerlin, Kverneland, Anders Handrup, Lauss, Martin, Hölmich, Lisbet Rosenkrantz, Hendel, Helle, Met, Özcan, Jönsson, Göran, Donia, Marco, Marie Svane, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252872/
https://www.ncbi.nlm.nih.gov/pubmed/34210820
http://dx.doi.org/10.1136/jitc-2021-002703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252872/
https://www.ncbi.nlm.nih.gov/pubmed/34210820
http://dx.doi.org/10.1136/jitc-2021-002703

Ejemplares similares